fluroxypyr methylheptyl ester: XRM-5084 is made up of 34.9% fluroxypyr methylheptyl ester and 65.1% proprietary emulsifier; used for the control of broadleaf vegetation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 54745 |
| CHEMBL ID | 1882270 |
| SCHEMBL ID | 161697 |
| MeSH ID | M0210272 |
| Synonym |
|---|
| 1-methylheptyl ((4-amino-3,5-dichloro-6-fluoropyridin-2-yl)oxy)acetate |
| fluroxypyr 1-methylheptyl ester |
| xrm 5084 |
| starane 250 |
| acetic acid, ((4-amino-3,5-dichloro-6-fluoro-2-pyridinyl)oxy)-, 1-methylheptyl ester |
| starane 2 |
| fluroxypyr-meptyl [iso] |
| fluroxypyr meptyl |
| dowco 433 |
| starane |
| fluroxypyr-(1-methylheptyl) |
| einecs 279-752-9 |
| fluroxypyr-meptyl |
| 81406-37-3 |
| 1-methylheptyl [(4-amino-3,5-dichloro-6-fluoropyridin-2-yl)oxy]acetate |
| NCGC00168311-01 |
| octan-2-yl 2-(4-amino-3,5-dichloro-6-fluoropyridin-2-yl)oxyacetate |
| A836460 |
| octan-2-yl 2-[4-azanyl-3,5-bis(chloranyl)-6-fluoranyl-pyridin-2-yl]oxyethanoate |
| 1-methylheptyl 2-[(4-amino-3,5-dichloro-6-fluoro-2-pyridyl)oxy]acetate |
| A840123 |
| 2-[(4-amino-3,5-dichloro-6-fluoro-2-pyridinyl)oxy]acetic acid octan-2-yl ester |
| NCGC00168311-02 |
| fluroxypyr methylheptyl ester |
| 9w47m4yj3q , |
| unii-9w47m4yj3q |
| NCGC00254801-01 |
| dtxsid5034303 , |
| tox21_300897 |
| cas-81406-37-3 |
| dtxcid3014303 |
| fluroxypyr-1-methylheptyl ester |
| 1-methylheptyl (4-amino-3,5-dichloro-6-fluoro-2-pyridyloxy)acetate |
| FT-0630892 |
| acetic acid, 2-[(4-amino-3,5-dichloro-6-fluoro-2-pyridinyl)oxy]-, 1-methylheptyl ester |
| AM20061523 |
| AKOS015895875 |
| fluroxypyr 1-methylheptyl ester [mi] |
| widematch s |
| dowco-433 |
| SCHEMBL161697 |
| 1-methylheptyl (4-amino-3,5-dichloro-6-fluoro-2-pyridinyloxy)acetate |
| 2-octanyl [(4-amino-3,5-dichloro-6-fluoro-2-pyridinyl)oxy]acetate |
| W-104211 |
| CHEMBL1882270 |
| [(4-amino-3,5-dichloro-6-fluoro-2-pyridinyl)oxy]acetic acid 1-methylheptyl ester |
| acetic acid, [(4-amino-3,5-dichloro-6-fluoro-2-pyridinyl)oxy]-, 1-methylheptyl ester |
| fluroxypyr methyl heptyl |
| F1213 |
| fluroxypyr-1-methylheptyl ester, pestanal(r), analytical standard |
| octan-2-yl 2-(4-amino-3,5-dichloro-6-fluoropyridin-2-yloxy)acetate |
| 1-methylheptyl[(4-amino-3,5-dichloro-6-fluoropyridin-2-yl)oxy]acetate |
| mfcd00144318 |
| AS-15363 |
| Q27273305 |
| D90700 |
| CS-0128796 |
| HY-136371 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Of all the tested compounds, FP was most toxic to the rat hepatocytes." | ( Stereoselective metabolism and toxicity of the herbicide fluroxypyr methylheptyl ester in rat hepatocytes. Jiang, J; Li, R; Shen, Z; Wang, X; Xu, X; Zhou, Z, 2011) | 0.61 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Altogether, these findings strongly support the hypothesis that surfactants contribute to increased cytotoxicity of PPPs and do so by increasing the bioavailability of the respective active substances." | ( Effects of co-formulants on the absorption and secretion of active substances in plant protection products in vitro. Bloch, D; Fischer, BC; Karaca, M; Marx-Stoelting, P; Tralau, T; Willenbockel, CT, 2021) | 0.62 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " It showed that fluroxypyr-meptyl may be safe to use according to the recommended dosage suggested by the corporation." | ( Dissipation and residues of fluroxypyr-meptyl in rice and environment. Pan, C; Wang, L; Xu, J; Zhao, P, 2011) | 0.37 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 44.6684 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 40.9240 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| AR protein | Homo sapiens (human) | Potency | 10.2212 | 0.0002 | 21.2231 | 8,912.5098 | AID588516; AID743036 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 68.5896 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 61.1306 | 0.0010 | 22.6508 | 76.6163 | AID1224839 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 54.9410 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 40.9944 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID588544; AID588546 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 74.1691 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 50.1187 | 0.0054 | 28.0263 | 1,258.9301 | AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 27.3060 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 14.1254 | 0.0010 | 24.5048 | 61.6448 | AID588535 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 42.8000 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 44.6684 | 0.0237 | 23.2282 | 63.5986 | AID588541 |
| caspase-3 | Homo sapiens (human) | Potency | 68.5896 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 76.9588 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 61.1306 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0016 | 28.0151 | 77.1139 | AID1259395 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 54.9410 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.6448 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 31.7182 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 108.8295 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 31.6228 | 0.0100 | 39.5371 | 1,122.0200 | AID588545 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 68.5896 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 61.6448 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 68.5896 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (7.69%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||